文献速递药物不良反应与药物警戒特殊人群用药

自闭症谱系障碍药物治疗:随机BAART临床试验结果

Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
PubMed 文献 · Pharmacotherapy · 2019-05-29

所有患者在第一周后异常行为量表易激惹子量表显著改善并持续至少22周;利培酮组改善最大,第3和6周显著优于阿立哌唑组;体重增加阿立哌唑组初期显著少于利培酮组,但延伸期差异不显著。

要点

  • 阿立哌唑和利培酮均在一周内改善自闭症患者易激惹症状,疗效持续至少22周。
  • 利培酮在多个评估期改善更优,第3和6周显著优于阿立哌唑。
  • 初期体重增加阿立哌唑显著少于利培酮,但长期差异不显著。

核心结论

  • 自闭症谱系障碍药物治疗可在一周内带来行为改善并持续至少22周。
  • 利培酮初期体重增加多于阿立哌唑,但试验结束时差异不显著。
  • 本试验支持选用FDA批准药物作为自闭症谱系障碍初始药物治疗。

研究设计与样本

  • 随机双盲平行组研究,在三个学术医学中心和一个私人儿科诊所进行。
  • 患者随机接受阿立哌唑(31例)或利培酮(30例)治疗10周,剂量遵循FDA标签,允许每周调整至第4周,之后固定剂量6周。

主要发现

  • 基线时阿立哌唑组与利培酮组疾病严重程度无显著差异。
  • 所有患者异常行为量表易激惹子量表在第一周后显著改善,并持续剩余9周及延伸期。
  • 利培酮组在每个评估期改善最大,第3和6周统计学显著优于阿立哌唑组(p<0.05)。
  • 剂量滴定期无剂量限制性不良事件。
  • 阿立哌唑组平均体重增加在第4周(0.62 vs 1.38 kg,p=0.033)和第10周(1.61 vs 3.31 kg,p<0.001)显著少于利培酮组,但完成3个月延伸期的31名患者中差异不显著(4.36 vs 5.55 kg,p=0.26)。

临床怎么用

  • 对于自闭症谱系障碍患者的初始药物治疗,可考虑选用FDA批准的阿立哌唑或利培酮。
  • 利培酮可能提供更优的短期行为改善,但需注意初期体重增加风险高于阿立哌唑。
  • 治疗早期应监测行为改善及体重变化,长期体重差异可能缩小。

局限性

  • 样本量较小,61名随机分配,51名完成10周试验,31名完成延伸期。
  • 研究仅包括儿童和青少年自闭症障碍患者,结论不适用于其他年龄或诊断人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The objective of this trial, Biomarkers in Autism of Aripiprazole and Risperidone Treatment (BAART), was to provide support and guidance for an evidence-based approach for the selection and monitoring of initial pharmacotherapy in patients with autism by assessing predictors of efficacy, tolerability, and safety. This randomized double-blind parallel-group study was conducted in three academic medical centers and a single private pediatric practice. Eighty children or adolescents (aged 6-17 yrs) with autistic disorder were enrolled, and 61 patients were randomized to the study drug. Of those patients, 51 completed the 10-week trial, and 31 completed an optional 12-week blinded extension phase. All patients were treated with 2 weeks of placebo before random assignment to receive aripiprazole (31 patients) or risperidone (30 patients) for 10 weeks. Sixteen placebo responders (20%) were excluded from further analysis. Drug dosing followed U.S. Food and Drug Administration (FDA) labeling, and weekly dosage adjustments were allowed until week 4; patients were then maintained on a fixed dose for 6 additional weeks. Safety, physical, and psychological assessments were recorded weekly or every 2 weeks. No significant differences in severity of illness between the aripiprazole and risperidone groups were noted at baseline. All patients significantly improved on the Aberrant Behavior Checklist-Irritability subscale after 1 week and continued for the remaining 9 weeks and the extension phase. Improvement was greatest in the risperidone group at every assessment period and was statistically significantly better than that in the aripiprazole group at weeks 3 and 6 (p<0.05). No dose-limiting adverse events occurred during the dose-titration period. Mean weight gain in the aripiprazole group was significantly less than that in the risperidone group at week 4 (0.62 vs 1.38 kg, p=0.033) and week 10 (1.61 vs 3.31 kg, p<0.001), but the difference became nonsignificant for the 31 patients completing the 3-month extension phase (4.36 vs 5.55 kg, p=0.26). Pharmacotherapy of patients with autism spectrum disorder resulted in behavioral improvement within 1 week and lasted at least 22 weeks. Weight gain occurred to a greater degree with risperidone than aripiprazole initially, but the differences became nonsignificant by the end of the trial. Our trial supports previous results of drug efficacy and safety in patients with autism spectrum disorder from other trials and extends the evidence-based support for choosing an FDA-approved drug for initial pharmacotherapy for autism spectrum disorder.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. DeVane CL, Charles JM, Abramson RK, et al. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial. Pharmacotherapy. 2019. PMID: 31063671. doi:10.1002/phar.2271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。